Hookipa Historical Financial Ratios

HOOK Stock

USD 2.41 0.13 5.12%

Hookipa Pharma is recently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.81 or Days Sales Outstanding of 300 will help investors to properly organize and evaluate Hookipa Pharma financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

About Hookipa Financial Ratios Analysis

Hookipa PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Hookipa Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Hookipa financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Hookipa Pharma history.

Hookipa Pharma Financial Ratios Chart

At this time, Hookipa Pharma's Days Payables Outstanding is quite stable compared to the past year. Income Quality is expected to rise to 0.88 this year, although the value of Days Sales Outstanding will most likely fall to 299.96.

Price To Sales Ratio Days Sales Outstanding Payables Turnover Capex To Revenue

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Hookipa Pharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Hookipa Pharma sales, a figure that is much harder to manipulate than other Hookipa Pharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most ratios from Hookipa Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Hookipa Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.At this time, Hookipa Pharma's Days Payables Outstanding is quite stable compared to the past year. Income Quality is expected to rise to 0.88 this year, although the value of Days Sales Outstanding will most likely fall to 299.96.

	2021	2022	2023	2024 (projected)
Current Ratio	3.69	4.13	3.5	3.33
Net Debt To EBITDA	0.8	1.77	1.43	2.71

Current Ratio Net Debt To E B I T D A

Hookipa Pharma fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.59	-0.83	-0.75	0.85	0.75	0.82	-0.59	1.0	0.74	0.89	0.15	0.86	0.37	-0.05	-0.15	-0.69	-0.98	0.76	0.16	-0.98	0.37	0.58	0.9	-0.98	-0.98
Ptb Ratio	-0.59		0.48	0.5	-0.44	-0.42	-0.57	1.0	-0.59	-0.41	-0.8	-0.07	-0.48	-0.19	0.43	0.0	0.38	0.71	-0.42	-0.1	0.72	-0.82	-0.29	-0.8	0.71	0.71
Days Sales Outstanding	-0.83	0.48		0.63	-0.64	-0.57	-0.71	0.48	-0.84	-0.58	-0.68	-0.06	-0.75	-0.34	0.03	0.3	0.59	0.81	-0.4	-0.58	0.81	-0.46	-0.85	-0.69	0.82	0.81
Book Value Per Share	-0.75	0.5	0.63		-0.43	-0.84	-0.75	0.5	-0.75	-0.81	-0.52	0.31	-0.85	-0.34	0.09	-0.01	0.98	0.74	-0.28	0.01	0.74	-0.61	-0.23	-0.54	0.74	0.74
Free Cash Flow Yield	0.85	-0.44	-0.64	-0.43		0.7	0.44	-0.44	0.85	0.72	0.86	0.1	0.79	0.6	0.18	-0.5	-0.34	-0.8	0.79	0.28	-0.81	0.05	0.45	0.87	-0.8	-0.8
Operating Cash Flow Per Share	0.75	-0.42	-0.57	-0.84	0.7		0.51	-0.42	0.75	1.0	0.6	-0.5	0.97	0.77	0.02	-0.44	-0.77	-0.72	0.34	0.11	-0.72	0.4	0.11	0.62	-0.72	-0.72
Capex To Depreciation	0.82	-0.57	-0.71	-0.75	0.44	0.51		-0.57	0.82	0.47	0.66	0.23	0.6	-0.03	-0.39	0.33	-0.74	-0.86	0.56	-0.15	-0.85	0.56	0.5	0.67	-0.86	-0.85
Pb Ratio	-0.59	1.0	0.48	0.5	-0.44	-0.42	-0.57		-0.59	-0.41	-0.8	-0.07	-0.48	-0.19	0.43	0.0	0.38	0.71	-0.42	-0.1	0.72	-0.82	-0.29	-0.8	0.71	0.71
Ev To Sales	1.0	-0.59	-0.84	-0.75	0.85	0.75	0.82	-0.59		0.74	0.89	0.15	0.86	0.36	-0.05	-0.15	-0.69	-0.98	0.76	0.16	-0.98	0.38	0.59	0.9	-0.98	-0.98
Free Cash Flow Per Share	0.74	-0.41	-0.58	-0.81	0.72	1.0	0.47	-0.41	0.74		0.6	-0.52	0.97	0.81	0.03	-0.5	-0.73	-0.71	0.32	0.16	-0.71	0.39	0.12	0.62	-0.71	-0.71
Roic	0.89	-0.8	-0.68	-0.52	0.86	0.6	0.66	-0.8	0.89	0.6		0.26	0.7	0.35	-0.14	-0.19	-0.41	-0.92	0.82	0.17	-0.92	0.43	0.51	1.0	-0.92	-0.92
Inventory Turnover	0.15	-0.07	-0.06	0.31	0.1	-0.5	0.23	-0.07	0.15	-0.52	0.26		-0.35	-0.7	0.07	0.53	0.26	-0.13	0.6	-0.13	-0.14	-0.28	0.44	0.22	-0.14	-0.14
Net Income Per Share	0.86	-0.48	-0.75	-0.85	0.79	0.97	0.6	-0.48	0.86	0.97	0.7	-0.35		0.72	0.06	-0.46	-0.77	-0.83	0.44	0.27	-0.83	0.41	0.35	0.73	-0.82	-0.83
Days Of Inventory On Hand	0.37	-0.19	-0.34	-0.34	0.6	0.77	-0.03	-0.19	0.36	0.81	0.35	-0.7	0.72		0.08	-0.88	-0.23	-0.35	0.02	0.4	-0.35	0.17	-0.03	0.37	-0.34	-0.35
Payables Turnover	-0.05	0.43	0.03	0.09	0.18	0.02	-0.39	0.43	-0.05	0.03	-0.14	0.07	0.06	0.08		-0.32	0.02	0.23	0.07	0.37	0.23	-0.61	0.17	-0.16	0.23	0.23
Capex To Revenue	-0.15	0.0	0.3	-0.01	-0.5	-0.44	0.33	0.0	-0.15	-0.5	-0.19	0.53	-0.46	-0.88	-0.32		-0.11	0.1	0.09	-0.7	0.1	0.08	-0.14	-0.2	0.1	0.1
Cash Per Share	-0.69	0.38	0.59	0.98	-0.34	-0.77	-0.74	0.38	-0.69	-0.73	-0.41	0.26	-0.77	-0.23	0.02	-0.11		0.66	-0.24	0.06	0.66	-0.52	-0.24	-0.43	0.66	0.66
Pocfratio	-0.98	0.71	0.81	0.74	-0.8	-0.72	-0.86	0.71	-0.98	-0.71	-0.92	-0.13	-0.83	-0.35	0.23	0.1	0.66		-0.73	-0.11	1.0	-0.51	-0.54	-0.93	1.0	1.0
Interest Coverage	0.76	-0.42	-0.4	-0.28	0.79	0.34	0.56	-0.42	0.76	0.32	0.82	0.6	0.44	0.02	0.07	0.09	-0.24	-0.73		-0.15	-0.73	-0.06	0.38	0.81	-0.73	-0.73
Capex To Operating Cash Flow	0.16	-0.1	-0.58	0.01	0.28	0.11	-0.15	-0.1	0.16	0.16	0.17	-0.13	0.27	0.4	0.37	-0.7	0.06	-0.11	-0.15		-0.12	0.09	0.67	0.17	-0.11	-0.12
Pfcf Ratio	-0.98	0.72	0.81	0.74	-0.81	-0.72	-0.85	0.72	-0.98	-0.71	-0.92	-0.14	-0.83	-0.35	0.23	0.1	0.66	1.0	-0.73	-0.12		-0.52	-0.54	-0.94	1.0	1.0
Days Payables Outstanding	0.37	-0.82	-0.46	-0.61	0.05	0.4	0.56	-0.82	0.38	0.39	0.43	-0.28	0.41	0.17	-0.61	0.08	-0.52	-0.51	-0.06	0.09	-0.52		0.17	0.44	-0.51	-0.51
Income Quality	0.58	-0.29	-0.85	-0.23	0.45	0.11	0.5	-0.29	0.59	0.12	0.51	0.44	0.35	-0.03	0.17	-0.14	-0.24	-0.54	0.38	0.67	-0.54	0.17		0.49	-0.55	-0.54
Roe	0.9	-0.8	-0.69	-0.54	0.87	0.62	0.67	-0.8	0.9	0.62	1.0	0.22	0.73	0.37	-0.16	-0.2	-0.43	-0.93	0.81	0.17	-0.94	0.44	0.49		-0.93	-0.93
Ev To Operating Cash Flow	-0.98	0.71	0.82	0.74	-0.8	-0.72	-0.86	0.71	-0.98	-0.71	-0.92	-0.14	-0.82	-0.34	0.23	0.1	0.66	1.0	-0.73	-0.11	1.0	-0.51	-0.55	-0.93		1.0
Pe Ratio	-0.98	0.71	0.81	0.74	-0.8	-0.72	-0.85	0.71	-0.98	-0.71	-0.92	-0.14	-0.83	-0.35	0.23	0.1	0.66	1.0	-0.73	-0.12	1.0	-0.51	-0.54	-0.93	1.0

Click cells to compare fundamentals

Hookipa Pharma Account Relationship Matchups

Hookipa Pharma fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	182.91	14.77	4.16	3.73	3.8	3.61
Ptb Ratio	18.53	1.85	0.86	0.52	0.85	0.81
Days Sales Outstanding	297.3	385.0	418.78	563.86	349.44	299.96
Book Value Per Share	6.6	59.85	27.23	15.63	9.51	13.59
Free Cash Flow Yield	(0.02)	(0.14)	(1.03)	(0.47)	(0.81)	(0.77)
Operating Cash Flow Per Share	(2.34)	(15.08)	(20.07)	(3.05)	(6.09)	(6.39)
Capex To Depreciation	3.36	1.39	0.57	2.71	1.17	2.18
Pb Ratio	18.53	1.85	0.86	0.52	0.85	0.81
Ev To Sales	174.32	8.0	1.1	(3.78)	(1.69)	(1.6)
Free Cash Flow Per Share	(2.45)	(15.99)	(23.89)	(3.81)	(6.53)	(6.85)
Roic	(0.33)	(0.25)	(0.86)	(0.69)	(1.06)	(1.01)
Net Income Per Share	(2.41)	(16.9)	(23.0)	(9.9)	(8.63)	(9.06)
Payables Turnover	6.01	49.06	6.63	0.53	0.66	0.28
Sales General And Administrative To Revenue	1.4	0.92	0.94	1.32	0.93	1.18
Research And Ddevelopement To Revenue	3.88	2.8	4.49	4.82	4.29	3.09
Capex To Revenue	0.17	0.12	0.68	0.35	0.21	0.24
Cash Per Share	6.34	54.89	20.34	17.3	12.39	13.49
Pocfratio	(52.34)	(7.35)	(1.16)	(2.66)	(1.33)	(1.4)
Interest Coverage	(58.25)	(67.79)	(90.95)	(106.48)	(308.18)	(292.77)
Capex To Operating Cash Flow	(0.0479)	(0.0603)	(0.19)	(0.25)	(0.0723)	(0.0759)
Pfcf Ratio	(49.95)	(6.94)	(0.98)	(2.12)	(1.24)	(1.3)
Days Payables Outstanding	7.44	55.02	689.25	556.11	1.3K	1.3K
Income Quality	0.97	0.89	0.87	0.31	0.71	0.88
Ev To Operating Cash Flow	(49.88)	(3.98)	(0.31)	2.69	0.59	0.62
Pe Ratio	(50.75)	(6.56)	(1.01)	(0.82)	(0.94)	(0.99)
Return On Tangible Assets	(0.3)	(0.23)	(0.6)	(0.38)	(0.51)	(0.53)
Ev To Free Cash Flow	(47.6)	(3.75)	(0.26)	2.15	0.55	0.58
Earnings Yield	(0.0197)	(0.15)	(0.99)	(1.22)	(1.07)	(1.12)
Net Debt To E B I T D A	2.62	3.39	0.8	1.77	1.43	2.71
Current Ratio	8.68	8.11	3.69	4.13	3.5	3.33
Tangible Book Value Per Share	6.6	59.85	27.23	15.63	9.51	13.59
Receivables Turnover	1.23	0.95	0.87	0.65	1.04	1.16
Graham Number	18.92	150.86	118.72	59.01	42.96	46.29
Shareholders Equity Per Share	6.6	59.85	27.23	15.63	9.51	13.59
Debt To Equity	0.04	0.0291	0.0559	0.0409	0.0307	0.0238
Capex Per Share	0.11	0.91	3.82	0.77	0.44	0.71

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:

How To Invest In Hookipa

Details

Is Hookipa Stock a good investment?

Details

What is Hookipa Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.67)

Revenue Per Share

4.403

Quarterly Revenue Growth

(0.52)

Return On Assets

(0.20)

Return On Equity

(0.49)

The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Hookipa Historical Financial Ratios

About Hookipa Financial Ratios Analysis

Hookipa Pharma Financial Ratios Chart

Price To Sales Ratio

Payables Turnover

Capex To Revenue

Hookipa Pharma fundamentals Correlations

Hookipa Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hookipa Pharma fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Roe	+ 1.0	Roic
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Pe Ratio	- 0.98	Ev To Sales
Ev To Operating Cash Flow	- 0.98	Ev To Sales
Pfcf Ratio	- 0.98	Ev To Sales
Pocfratio	- 0.98	Ev To Sales
Pe Ratio	- 0.98	Price To Sales Ratio
Ev To Operating Cash Flow	- 0.98	Price To Sales Ratio